18. EVENTS SUBSEQUENT TO BALANCE DATE On 23 January 2025, the Company provided revenue guidance to the ASX for the FY 30 June 2025 to be $25 million. The guidance was based on revenue achieved to date and from, ■ growing its manufacturing and pharmaceutical services business customer base, ■ growing market share for its Dr Watson® branded pharmaceutical products in Australia, ■ launching Dr Watson® and BLS branded medical cannabis products in the UK and European markets, and ■ signing long term contracts with market leading distributors of medical cannabis products. No other matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect: a) The Company’s operations in future financial periods; or b) The results of those operations in future financial periods; or c) The Company’s state of affairs in future financial periods.
BXN Price at posting:
3.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)